Dr. Emmanuel Antonarakis on AR-V7 and Response to Taxanes in mCRPC

February 27, 2015
Emmanuel S. Antonarakis, MBBCh

Emmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, discusses a study looking at androgen receptor splice variant 7 (AR-V7) in metastatic castration-resistant prostate cancer (mCRPC).

Emmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, discusses a study looking at androgen receptor splice variant 7 (AR-V7) in metastatic castration-resistant prostate cancer (mCRPC).

In a previous study, it was seen that the presence of AR-V7 was associated with little or no response to the agents abiraterone and enzalutamide.

In this analysis, researchers looked at the correlation of the presence of AR-V7 and response to taxane chemotherapies. Antonarakis says that AR-V7 did not cause primary resistance to taxane chemotherapies. If a patient is diagnosed with AR-V7 in their tumors, they may not respond to abiraterone or enzalutamide, but he has a decent chance of responding to chemotherapy.

<<<

View more from the 2015 GU Cancer Symposium


x